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Abstract
Background: T lymphocytes are orchestrators of adaptive immunity. Naïve T cells may differentiate into Th1, Th2,
Th17 or iTreg phenotypes, depending on environmental co-stimulatory signals. To identify genes and pathways
involved in differentiation of Jurkat T cells towards Th1 and Th2 subtypes we performed comprehensive
transcriptome analyses of Jurkat T cells stimulated with various stimuli and pathway inhibitors. Results from these
experiments were validated in a human experimental setting using whole blood and purified CD4+ Tcells.
Results: Calcium-dependent activation of T cells using CD3/CD28 and PMA/CD3 stimulation induced a Th1 expression
profile reflected by increased expression of T-bet, RUNX3, IL-2, and IFNg, whereas calcium-independent activation via
PMA/CD28 induced a Th2 expression profile which included GATA3, RXRA, CCL1 and Itk. Knock down with siRNA and
gene expression profiling in the presence of selective kinase inhibitors showed that proximal kinases Lck and PKCθ are
crucial signaling hubs during T helper cell activation, revealing a clear role for Lck in Th1 development and for PKCθ in
both Th1 and Th2 development. Medial signaling via MAPkinases appeared to be less important in these pathways,
since specific inhibitors of these kinases displayed a minor effect on gene expression. Translation towards a primary,
whole blood setting and purified human CD4+ T cells revealed that PMA/CD3 stimulation induced a more pronounced
Th1 specific, Lck and PKCθ dependent IFNg production, whereas PMA/CD28 induced Th2 specific IL-5 and IL-13
production, independent of Lck activation. PMA/CD3-mediated skewing towards a Th1 phenotype was also reflected in
mRNA expression of the master transcription factor Tbet, whereas PMA/CD28-mediated stimulation enhanced GATA3
mRNA expression in primary human CD4+ Tcells.
Conclusions: This study identifies stimulatory pathways and gene expression profiles for in vitro skewing of T
helper cell activation. PMA/CD3 stimulation enhances a Th1-like response in an Lck and PKCθ dependent fashion,
whereas PMA/CD28 stimulation results in a Th2-like phenotype independent of the proximal TCR-tyrosine kinase
Lck. This approach offers a robust and fast translational in vitro system for skewed T helper cell responses in Jurkat
T cells, primary human CD4+ Tcells and in a more complex matrix such as human whole blood.
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Background
Activation of T helper 0 (Th0) cells leads to differentia-
tion into several lineages. These lineages include the
Th1 and Th2 subsets as well as the more recently
described subsets such as induced T regulatory cells and
Th17 cells. The Th1 cells protect against intracellular
pathogens and are in general characterized by their abil-
ity to produce IFNg, IL-2 and TNFa and express the
Th1-specific transcription factor T-bet. The Th2 subset,
which is involved in the defense against extracellular
pathogens, is characterized by the production of IL-4,
IL-5 and IL-13 and is controlled by the master tran-
scription factor GATA3 [1,2].
In a proper functioning immune system, these different
T helper subsets are well-balanced and co-operate to
eliminate invading pathogens and to maintain homeosta-
sis. Hyper activation of one T helper subset, however,
can tip the balance from health towards disease, in which
Th2-overshoot can lead to inappropriate immune
responses leading to diseases like allergy and asthma.
Alternatively, overshoot towards a Th1 or Th17-pheno-
type can cause autoimmune diseases, like rheumatoid
arthritis and multiple sclerosis [3,4].
For effective CD4 T cell activation, the antigen-
presenting cell (APC) provides a key contact point to facil-
itate T cell activation and polarization towards different T
helper subsets. A crucial event in this process is the inter-
action between the antigen presented via the MHCII
receptor and the TCR receptor (signal 1). The nature of
activation, defined by the strength of the TCR stimulation,
can affect T helper cell polarization towards Th1 or Th2,
in which a high affinity interaction favors Th1 develop-
ment and low affinity drives Th2 development [5-8].
Besides the TCR signal transduction, an additional signal
is provided by the APC in the form of a co-stimulatory
signal (signal 2). This signal is provided via CD28-B7 inter-
action and has been shown to be important for effective T
cell activation [9]. Furthermore, CD28-mediated co-stimu-
lation has been implicated in effective polarization of T
cells towards a Th2 phenotype [10,11]. Also other co-sti-
mulatory molecules, including ICOS and OX40, have been
positively correlated with Th2 differentiation [12,13]. The
results from these studies underline the importance of
both signal 1 and signal 2, but also underline the complex-
ity of these integrated signaling pathways.
The cascade of biochemical events, linking cell surface
receptor engagement to cellular responses has been a
focus of many studies. Detailed investigation of these sig-
nal transduction events has led to identification and func-
tional characterization of many kinases and phosphatases
downstream of the TCR and CD28-receptor. TCR ligation
results in the recruitment of p56Lck (Lck), a proximal
TCR Src family kinase, which kick-starts the signal trans-
duction cascade leading to phosphorylation of the ITAM
motifs in the TCR, which recruits and activates ZAP70
[14]. This initial step leads to the activation of PLCg that
hydrolyzes PIP2 into IP3, which is the second messenger
molecule responsible for the sustained intracellular cal-
cium flux in T cells. CD28-ligation on T cells results in
the recruitment of PI3K, with PIP2 and PIP3, which serve
as pleckstrin homology (PH) domain membrane anchors.
Via this mechanism PDK1 and PKB/Akt are recruited and
regulate several pathways that increase cellular metabolism
[15]. Additionally, CD28-signaling has been shown to initi-
ate NFB signaling, via a mechanism that is functionally
linked through recruitment of PKCθ to CD28 in the
immunological synapse [16-18].
Members of the Mitogen-activated protein kinase family,
which can be activated via TCR signaling, also play a role
in the differentiation of Th1 and Th2 subsets. In a thor-
ough review by Dong et al., the role of p38, JNK and ERK
in T helper cell differentiation has been outlined [19]. ERK
is important for Th2 differentiation, whereas p38 and
JNK2 appear to be involved in Th1 development.
TCR/CD3 stimulation and CD28 stimulation alone are
weak activators of T cell signaling. It is generally conceived
that CD28 signaling merely acts as a signal potentiator on
top of the initiator signal mediated via the TCR/CD3. Led-
better and June et al. described that CD28 stimulation in
the absence of cross-linking on top of PMA stimulation
can activate T cells, without increasing calcium flux
[20,21]. This suggests that co-stimulatory pathways syner-
gize with biochemical pathways induced via the TCR.
Whether CD28 ligation, in the absence of TCR signaling,
leads to activation and differentiation has not been fully
explored.
These findings show that effective T cell activation and
differentiation towards effector subsets is the result of
precise integration of multiple signaling routes. To
explore the pathways underlying these distinct routes
towards T cell activation and differentiation we used
comprehensive biochemical characterization and gene
expression profiling of Jurkat T cells that were activated
with various co-stimulatory signals in the presence of
various inhibitors of specific signaling routes.
With this approach we identified specific PMA/CD3 and
PMA/CD28 signal transduction and genomic fingerprints.
PMA/CD3 stimulation induced a Th1 phenotype, depen-
dent on both Lck and PKCθ, whereas PMA/CD28 stimula-
tion, which is independent of TCR-mediated activation of
Lck, resulted in a profound activation of T cells, skewing
towards a Th2 phenotype.
Results and discussion
Activation of Jurkat T cells by various stimuli leads to
differential signaling fingerprints
Jurkat T cells were activated by anti-CD3, anti-CD28,
PMA, or ionomycin or combinations of these single
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stimuli, in order to map the contribution of these
stimuli towards the activation of proximal, medial
and distal signal transduction pathways. As shown in
Figure 1A, CD3-stimulation and ionomycin/PMA were
able to increase intracellular levels of Ca2+. Interestingly,
neither CD28 nor PMA stimulation alone, affected
intracellular Ca2+ levels. As expected, CD3-signaling
resulted in an Lck-dependent phosphorylation of ZAP70
(Figure 1B). Stimuli containing PMA directly activated
the MAPK pathway, which is reflected by the phosphor-
ylation of ERK, P38 and JNK (Figure 1B). Furthermore,
PMA addition directly activated PKC which was not
reflected in the autophosphorylation of PKCθ, but was
clearly detectable on the phosphorylation of the PKC
substrate MARCKS (Figure 1B). CD3-mediated stimula-
tions and PMA-induced stimulations resulted both in
the activation of AP1 family transcription factors c-Jun
and ATF2 (Figure 1B). Analysis of nuclear translocation
of NFATc1 and c-Jun (AP1)/NFB p65, as part of the dis-
tal signaling events revealed that indeed CD3-mediated
signaling induced both NFAT and c-Jun/NFB, of which
the latter pathways were potentiated by CD28-mediated
signaling (Figure 1C). In line with the calcium release
from the ER, PMA or PMA/CD28-mediated signaling did
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Figure 1 Signal transduction in Jurkat T cells. Jurkat T cells were stimulated with different combinations of stimuli in order to elucidate the
different signal transduction pathways. A; Jurkat T cells were stimulated as indicated and intracellular Ca2+ release was monitored over/in time.
B; Intracellular signal transduction routes were charted via phosphoanalysis using western blot. Jurkat T cells were stimulated for 15 min using
different stimulations. Proximal (Lck, ZAP70, PKCθ and the PKC substrate MARCKs), medial (MAPK phosphorylation) and distal (c-Jun and ATF2)
signaling was monitored based on the phosphorylation status of the described proteins. C; Nuclear translocation of the transcription factors
NFAT, NFkB and c-Jun was evaluated 15 minutes after stimulation.
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not induce NFAT nuclear translocation but highly acti-
vated the CD28 responsive element transcription factors
c-Jun and NFB p65 (Figure 1C). These results indicate
that two distinct co-stimulatory profiles can be identified.
A CD3/28 and PMA/CD3 stimulus that signals via Lck,
increasing intracellular Ca2+ and activating NFAT, and a
PMA/CD28 calcium independent (co)-stimulatory activa-
tion signaling via PKCθ and MARCKS. Next, the molecu-
lar mechanisms involved in these signaling pathways were
further explored in genomics studies.
Differential regulation of genes after PMA/CD3 and CD3/
28 Vs PMA/CD28 stimulation
In order to further characterize the different signal trans-
duction events induced by different (co)-stimulatory sig-
nals, we performed a first gene expression experiment
with Jurkat T cells that were stimulated for 1 or 8 hours
with PMA/CD3, CD3/28 and PMA/CD28. It appeared
that after 1 hour a limited response on transcription level
was seen, whereas after 8 hours of stimulation, several
hundreds of genes were regulated. Furthermore, PMA/
CD3 and PMA/CD28 regulate more genes compared to
CD3/28, reflecting the strength of the stimuli used
(Figure 2). Multivariate analysis by principal component
analysis and hierarchical clustering showed that the 3 sti-
muli lead to clearly distinct gene expression profiles. At
both time points the profile induced by PMA/CD28 is
clearly distinct from the profiles induced by PMA/CD3
and CD3/28 (Figure 2).
Differentially regulated genes CCL1 and IL-2 are profile-
specific secreted proteins
Gene profiles of the differential stimuli were ranked on
the level of induction and evaluated on whether or not
the translated protein is secreted. This resulted in the
identification of the PMA/CD28-specific transcript CCL1
(Figure 3A), the CD3-specific transcripts IL-2 (Figure 3B)
and XCL1/2 (data not shown). Small but significant
inductions of these genes were observed after 1 hour of
stimulation for both CCL1 and IL-2. However, both
genes were highly induced after 8 hours of stimulation.
The secretion of the protein 24 hours after stimulation
reveals an identical profile compared to the mRNA
(Figure 3A/B, right hand panel).
Pathway profiling with multiple stimuli and inhibitors
To investigate the contribution of proximal, medial and
distal signaling events on the CD3/28, PMA/CD3 and
PMA/CD28 stimuli, we performed a second gene expres-
sion profiling experiment with different selective inhibi-
tors, including proximal kinase inhibitors Lck (A420983),
PKCθ (AEB071), medial MAPK inhibitors PD98059
(MEK/ERK), SP600125 (pan JNK), Org 48762-0 (P38) and
the distal Calcineurin (Cn) inhibitor Cyclosporin A (CsA).
Jurkat T cells were stimulated with PMA, CD28 and CD3
alone and combinations thereof in the presence of the
above mentioned inhibitors. Based on the results of the
first gene expression profiling experiment, we chose evalu-
ated gene expression after 8 hours of stimulation.
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CD3 + CD28
Overlap with
Number of
 probe sets CD3_PMA PMA_CD28 CD3_CD28
T= 1 hrs
CD3_PMA 338 1.00 0.53 0.83
PMA_CD28 194 0.92 1.00 0.89
CD3_CD28 319 0.88 0.54 1.00
T= 8 hrs
CD3_PMA 1567 1.00 0.72 0.42
PMA_CD28 1853 0.60 1.00 0.30
CD3_CD28 786 0.84 0.70 1.00
Figure 2 PMA/CD3 and CD3/28 stimulations differ from PMA/CD28 stimulation. The table shows the number of regulated probe sets and
their overlap at 1 and 8 hrs following stimulation with CD3/PMA, PMA/CD28 and CD3/CD28 (using a fold change cut off of 2 and a p-value cut
off of < 1.10-6). The right panel shows a hierarchical clustering of the data using the data for the regulated probe sets. Most of the variation is
caused by the time difference (1 hr vs 8 hrs). At both time points the PMA/CD28 stimulus was clearly different from the CD3/CD28 and CD3/
PMA stimulus. Repeating this analysis with different values for the fold change and p-value cut off yielded essentially the same results for the
multivariate analysis.
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A principal component analysis on the ratio data set is
shown in Additional file 1: Figure S1. It appeared that
the PMA/CD28, CD3/CD28 and PMA/CD3 co-stimuli
induced several hundreds of genes, whereas the effect of a
single stimulus was smaller, with the exception of the
PMA single stimulus (Additional file 1: Figure S1, Addi-
tional file 2: Table S1). The gene set induced by a PMA
stimulus showed a larger overlap with the genes induced
by the PMA/CD28 stimulus than with the CD3/PMA
induced gene set. Whereas PMA and CD3 as a single sti-
mulus induce a large number of genes, CD28 elicits only a
minor effect. It can be observed that CsA, AEB071 and
A420983 induce the largest effects on gene regulation,
whereas the inhibitors of the MAPK pathway only have a
minor effect on gene expression. This finding is corrobo-
rated by the number of regulated genes, showing that the
MAPK inhibitors only regulate a small number of genes
whereas A420983, CsA and AEB071 regulate many genes
(Additional file 2: Table S1). A420983 and CsA only show
a significant effect on the PMA/CD3 and CD3/CD28 path-
ways, in which the effect of CsA is smaller than the effect
of A420983. AEB071 is the only compound that shows
also a significant effect on the PMA/CD28 induced path-
way. These analyses were rerun with different settings for
the thresholds used for gene selection. In all cases similar
results were obtained indicating that the results were not
critical dependent on the thresholds settings that were
used.
Inspection of the profiles of CCL1 and IL-2 revealed
that CCL1 mRNA is highly induced via the PMA/CD28
pathway. This induction is depending on PKC signaling
and negatively regulated via Lck signaling. Apparently
this effect was upstream of Cn, since the inhibitor CsA
did not increase CCL1 mRNA induction (Figure 4A).
A
B
Figure 3 Differential regulation of IL-2 and CCL1. Jurkat T cells were activated for 1 and 8 hours using different stimuli (as indicated).
Differentially regulated genes of which the proteins were secreted were identified and the highest ranking genes were selected. A; regulation of
the CCL1 mRNA is highly and differentially regulated after PMA/CD28 stimulation. Right panel shows the validation of the mRNA levels on
protein level, secreted by activated Jurkat T cells. B; regulation of IL-2 mRNA is highly and differentially regulated after CD3/28 and PMA/CD3
stimulation. Right panel shows the validation of the mRNA levels on protein, secreted by activated Jurkat T cells.
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Figure 4 Involvement of signal transduction pathways on differentially regulated genes. Jurkat T cells were stimulated as indicated
previously and the involvement of different signaling pathways on gene regulation was elucidated using inhibitors of specific pathways,
including Lck (1 μM), PKC (10 μM), Calcineurin (1 μM), and MAPKs p38, JNK, and MEK/ERK (all 10 μM). A; Regulation of CCL1 mRNA in Jurkat T
cells after stimulation with PMA/CD28-, CD3/28- or PMA/CD3-and co-incubated and cultured for 8 hours in the presence or absence of signal
transduction pathway inhibitors. B; Regulation of IL-2 mRNA in Jurkat T cells after stimulation with PMA/CD28-, CD3/28- and PMA/CD3- and co-
incubated and cultured for 8 hours in the presence or absence of signal transduction pathway inhibitors. The height of the bars represent the
average intensity of 3 biological replicates, the error bars indicate the variation (min and max values). Significance of changes in expression level
between the stimulated sample and the sample that was stimulated in the presence of the pathway inhibitor is indicated as follows; *** P value
< 0.0001; ** 0.01 <P value > 0.001* 0.05 <P value > 0.01.
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As expected, PMA/CD3 and CD3/28 stimuli and to a
lesser extent PMA/CD28 resulted in a marked expression
of IL-2, which is highly depending on the Lck/Cn signal
transduction pathway, and the PKC pathway. Interest-
ingly inhibition of MAPK signaling (with the exception of
the MEK/ERK pathway) does not affect IL-2 mRNA
induction (Figure 4B). These effects on CCL1 and IL-2
production by inhibitors of the Lck/Cn and PKC pathway
were further substantiated in a full dose-response experi-
ment. Figure 5A shows that indeed AEB071 dose-depen-
dently inhibited PMA/CD28-induced CCL1 production,
which is slightly enhanced in the presence of an Lck inhi-
bitor and which is not affected by Cn inhibition via CsA.
IL-2 production can be blocked by inhibition of both the
Lck/Cn and PKC pathway (Figure 5B). The involvement
of Lck in the CD3-mediated pathway and PKC in the
CD3 and CD28-mediated pathways was further con-
firmed by the knock-down of both kinases under the dis-
tinct stimuli. Knock-down of Lck did not affect PMA/
CD28-induced CCL1 production, whereas knock-down
of PKCθ resulted in significant inhibition of both IL-2
and CCL1 (Figure 5C). These results clearly show that
PMA/CD28-induced gene profiles are highly depending
on PKCθ signaling pathways but are independent of Lck/
Cn and MAPK signaling pathways, whereas CD3-
mediated signaling pathways are dependent on both Lck/
Cn and PKCθ signal transduction and independent on
MAPK signaling events.
PMA/CD3, PMA/CD28 and CD3/CD28 induce distinct
genomic fingerprints
The above analysis indicated that treating Jurkat T-cells
with multiple combinations of stimuli and inhibitors high-
lights pathways that are regulated by specific combinations
of stimulus and inhibitor, revealing the involvement of cer-
tain kinases as signaling hub under specific stimulatory
conditions. In order to identify additional genes in the
pathways that are exemplified by CCL1 and IL-2, we
Figure 5 PMA/CD28-induced CCL1 production is not dependent on the Lck/Cn pathway. Jurkat T cells were stimulated using PMA/CD3
and PMA/CD28 in the presence of Lck (A420983), Cn (CsA) and PKC (AEB071) pathway inhibitors for 24 hours. Dose- response effects of the
inhibitors were evaluated on the production of CCL1, after PMA/CD28 stimulation (A) and IL-2 after PMA/CD3 stimulation (B) in supernatant of
the cell cultures. The data are representative for 3 independent experiments. C; Knock down of Lck and PKCθ resulted in a clear dose-dependent
reduction of the protein (500, 100, 20 nM siRNA). 24 hour culture supernatants were collected after stimulation with PMA/CD28 and PMA/CD3
and the effect of knock down on respectively CCL1 and IL-2 was determined. Data of two independent experiments are presented as mean +
SEM. Significance of differences are indicated by ** p < 0.01, *p < 0.05, # no difference using a one-way ANOVA with a Bonferroni’s post-hoc
test. N.b the values shown in this figure are log2 values no to be confused with the intensity values as shown in figure 3.
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searched for genes with similar profiles to these pathway
genes. Figure 6 shows genes related to CCL1, identified by
a strong up regulation following PMA/CD28 stimulation
only and a down regulation by AEB071. Interestingly,
besides CCL1, which is a chemo attractant for Th2 cells,
many Th2-associated genes co-clustered with CCL1,
including GATA3, Itk, RXRA, c-FLIP (CFLAR), ICOS and
the IL-31 receptor and also other genes that are associated
with Th2 development (See Figure 6; CCL1 gene cluster).
Likewise a very specific IL-2 profile can be constructed
by selecting genes that are up regulated under all three
conditions and down regulated by all three inhibitors,
and by which CsA is the weakest inhibitor (see Figure 6;
IL-2 cluster). In this gene cluster appeared to be Th1-
associated genes, including the Th1 master transcription
factor Tbet (TBX21), Th1 chemokine XCL1/2, IFNg,
granzyme, RUNX3, FASL, OX40L (TNFRSF4), CD27,
and the IL-21 receptor. Of note, inhibition of both Lck
Figure 6 Heatmap of stimulation dependent gene clusters. Top left panel: CCL1 cluster characterized by induction of genes exclusively
following CD28/PMA stimulation and subsequent repression by AEB071. Bottom left panel: IL-2 cluster characterized by induction of genes by all
stimulations, and down-regulated by A420983 and AEB071 and to a lesser extent by CsA. Top right panel: EGR1 cluster characterized by
induction of genes by all stimulations, but down-regulated only by AEB071 when stimulated with PMA/CD28 or PMA/CD3. A red color denotes
an up-regulation, a green color a down-regulation. The MAPK inhibitors induced very little regulation and have been omitted from this figure for
clarity. The gene lists shown in this figure, with extended annotation and their distance to the CCL1, IL-2 and EGR1 profiles are provided in
Additional files: File S1, S2 and S3.
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and Cn under PMA/CD3 stimulation enhanced the
expression of Th2 master transcription factors GATA3
and RXRA, but also peptidoglycan recognition protein 4
(PGLYRP4) and G protein-coupled receptor 84 (GPR84).
A third example is provided by genes clustering together
with EGR1, which show an up regulation by all stimuli but
are specifically regulated by AEB071 in all conditions and
only by A420983 after CD3/CD28 stimulus. Although IL-2
and EGR1 show a similar regulation by the stimuli used,
the profiles can clearly be discriminated by the effects of
the various inhibitors on their expression. The list of
genes that are shown in Figure 7 together with their anno-
tation and the correlation score to the CCL, IL-2 and
EGR1 profiles are shown in Additional file 1: Figure S1,
Additional file 2: Table S2, Additional file 3: Table S3
This analysis shows that by applying multiple stimuli
and selective compound treatments, pathways can be
unraveled at high resolution.
Translation of PMA/CD3 and PMA/CD28 stimulations;
differential modulation of primary T cell cytokine
responses in human donor blood
In order to assess whether the stimulation profiles and sig-
nal transduction profiles identified in Jurkat T-cells were
also relevant in a primary human setting, the stimulation
protocols were adapted and a primary assay was estab-
lished using healthy human donor whole blood. The effect
of differential stimulation was evaluated using IFNg and
IL-17 as Th1- and Th17-associated read-outs respectively
and both IL-5 and IL-13 as Th2-associated read-outs.
Stimulation of human whole blood cells with CD3/CD28
was unsuccessful: no cytokine release was detected. How-
ever, PMA/CD3 stimulation of human blood cells, resulted
in a high production of IFNg (Figure 7A). Interestingly,
INFg production levels were significantly lower after
PMA/CD28 stimulation. A similar observation was seen
when analyzing IL-17 production. Thus, higher production
levels of both IFNg and IL-17 were seen following PMA/
CD3 stimulation when compared to PMA/CD28 stimula-
tion. Furthermore, when analyzing Th2-associated IL-5
and IL-13 production, we found that PMA/CD28 stimula-
tion was superior to PMA/CD3 stimulation in enhancing
production of these cytokines (Figure 7B). Of note, CCL1
production could not be detected in this assay system
(data not shown). In aggregate, the data suggests that
PMA/CD28 stimulation favours Th2 responsiveness in
this assay. Since PMA/CD28 signaling was shown to be
independent of Lck, but mainly dependent on PKCθ,
whereas PMA/CD3 signaling was both Lck and PKCθ
dependent we evaluated the effect of both proximal
kinases in this human whole blood assay and evaluated
IFNg and IL-13 production since these cytokines were
most readily produced. Figure 7C shows that indeed
PMA/CD3-induced IFNg production is depending on
both Lck and PKCθ signaling, whereas PMA/CD28-
induced IL-13 production is Lck-independent and PKCθ
dependent. These results clearly show that the differential
stimulations identified in the Jurkat assay can be translated
towards a primary human cellular assay and are depending
on the same proximal signaling hubs. Furthermore, also in
this setting it can be observed that PMA/CD3 stimulation
diverges more towards a Th1-like phenotype, whereas
PMA/CD28 stimulation skews more towards a Th2-like
response.
PMA/CD3 stimulation of purified human CD4+ T cells
enhances Th1 activation, whereas PMA/CD28 potentiates
Th2 activation
Using purified human CD4+ T cells we validated the
effects observed on Jurkat T cells and in a primary human
whole blood assay setting. Of all stimuli used PMA/CD3
appeared to be the most powerful stimulus able to induce
IFNg production. Also in this setting inhibition of either
Lck using A-420983, or PKC using AEB071 completely
inhibited PMA/CD3 induced IFNg production. CD3/
CD28-mediated stimulation, which can be successfully
applied in this assay format induced IFNg production,
which was dependent on both Lck and PKC mediated sig-
nal transduction pathways. Of interest and comparable to
the effects observed on CCL1 production by Jurkat T cells,
Lck inhibition under PMA/CD28 stimulation did not inhi-
bit IFNg production and even appears to slightly enhance
IFNg production (Figure 8A). The observed effect on IFNg
production of the different stimuli is in line with the
effects observed on the induction of the Th1 master tran-
scription factor Tbet (Figure 8B). Both inhibition of Lck
and PKC reduced CD3/28 and PMA/CD3 mediated
induction of Tbet, whereas Lck inhibition did not affect
PMA/CD28-induced expression of Tbet.
PMA/CD28 was the most profound inducer of IL-13 in
CD4+ cells (Figure 8B). Interestingly IL-13 production
under al stimulatory conditions used is dependent on
PKC, whereas Lck inhibition does not affect IL-13 produc-
tion under PMA/CD3 or PMA/CD28 culture conditions.
Under all culture conditions inhibition of PKC reduced
IL-13, which was paralleled with reduced GATA3 expres-
sion (Figure 8D), whereas inhibition of Lck appeared to
promote Th2 dvelopment under all stimuli used, which
was reflected by enhanced expression of GATA3.
Conclusions
In this study we systematically explored pathways involved
in T cell activation by molecular profiling. We showed
that TCR (both CD3/28 and PMA/CD3) driven stimula-
tion profiles are truly distinct from co-stimulatory profiles
mediated via PMA/CD28. Secondly, using selective inhibi-
tors and siRNA we found that the proximal kinase Lck is
involved in CD3 and not PMA/CD28 activation, whereas
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Figure 7 PMA/CD3 and PMA/CD28 stimulation differentially modulate primary T cell cytokine responses in human healthy donor
blood. Healthy donor blood was stimulated with PMA/CD3 and PMA/CD28 and cultured for 24 hours in the presence or absence of pathway
inhibitors for Lck and PKC. Culture supernatants were analyzed on A; IFNg, IL-17 (Th1/17 cytokines) and B; IL-13 and IL-5 (Th2 cytokines). Figure C
shows the involvement of Lck (420983; 1 μM) and PKC (AEB071; 1 μM) signal transduction on PMA/CD3-induced IFNg production. Figure D
shows the effect of Lck (A-420983; 1 μM)) and PKC (AEB071; 1 μM) signal transduction pathways on PMA/CD28-induced IL-13 production. Data
are presented as results from 3 donors measured as biological duplicates. Significance of differences are presented as followed; * p < 0.05, **p <
0.01 using a one-way ANOVA with Dunnett’s post hoc testing.
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PKCθ appears to be a crucial central signaling kinase in
both TCR and PMA/CD28 (co)-stimulatory activation of
T cells. Finally, stimulations involving TCR/CD3 appear to
preferentially induce a Th1-like fingerprint, whereas lack
of TCR/CD3 signaling in the presence of PMA/CD28 sti-
mulation diverts T cells towards a Th2-like state.
It has been suggested that the strength of TCR-signaling
can regulate the fate determination of naive T cells; high-
potency signals skew towards Th1 differentiation, whereas
low potency signals promote Th2 differentiation [6,22].
Although TCR and co-stimulatory pathways have been
the focus of many studies in the previous decades, the
direct contribution of TCR stimulation vs. co-stimulatory
signals towards Th differentiation is not fully understood.
By stimulating T cells with PMA/CD3 and PMA/CD28 we
dissected signaling pathways and explored the activation
profiles. CD3-mediated signaling rapidly increased intra-
cellular Ca2+, a second messenger to activate many
Figure 8 PMA/CD3 and PMA/CD28 effects on purified primary human CD4+ T cells. Purified CD4+ T cells were stimulated with anti-CD3/
CD28, PMA/CD3 and PMA/CD28 and cultured for 24 hours in the presence or absence of pathway inhibitors for Lck (A420983; 1 μM) and PKC
(AEB071; 1 μM). Culture supernatants were analyzed for IFNg, production (A), mRNA expression of the Th1 master transcription factor T-bet (B),
the production of the Th2 cytokine IL-13 (C) and expression of the Th2 master transcription factor GATA3 (D). Message RNA expression was
normalized against ribosomal house hold gene RPL19. Data are presented of three independent experiments using purified human CD4+ T cells
from three different healthy donors. Data are presented as mean + SD. Significance of differences are indicated by ** p < 0.01, * p < 0.05, using
a mann-withney U-test.
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enzymes including Calcineurin, which resulted in an
increased nuclear translocation of NFATc1. Interestingly,
PMA/CD28 stimulation did not result in a Ca2+-mediated
response (and was therefore marked a calcium-indepen-
dent stimulation) but enhanced many of the co-stimula-
tory mediators including MAPK/AP1 and NFB signal
transduction. These results are in line with earlier studies
that showed differential effects of cyclosporine A (CsA)
and dexamethasone on CD3 vs CD28-mediated signaling,
which revealed that PMA/CD28 stimulation was insensi-
tive towards CsA-mediated Calcineurin inhibition in con-
trast to PMA/CD3 stimulation [20,23].
Gene expression induced by combinations of stimula-
tory signals revealed pathway-specific biomarkers or
fingerprints. PMA/CD3-induced gene profiles included
IL-2, IFNg, XCL1, granzyme B, and FASL, which have
been associated with a Th1 type of response [24,25].
Also, sustained NFAT signaling, which is also induced
via PMA/CD3 stimulation, has been shown to promote
Th1-like gene transcripts, including IFNg, FasL and
P-selectin glycoprotein ligand 1 [26]. Our results are
further substantiated by the finding that T-bet (TBX21),
the Th1 master transcription factor [27], and RUNX3,
which together with Tbet are crucial for inducing IFNg
and repressing IL-4 [28], were highly expressed under
PMA/CD3-stimulatory conditions.
PMA/CD28 stimulation does not induce a Ca2+ flux nor
does it increase nuclear translocation of NFAT. However
it provides the cell with a high level of co-stimulatory
signaling, and induces a completely distinct genomic fin-
gerprint compared to PMA/CD3 stimulation. Following
PMA/CD28 stimulation, Jurkat T cells highly expressed
CCL1/I309, a chemokine which is highly expressed during
a Th2-eosinophil response in allergic airway diseases
[29,30]. Lymphotoxin (LT), a cytokine which is associated
with a Th2-type of response controlling IgE production
[31], was also highly expressed under PMA/CD28 stimula-
tion. In conjunction with this finding, the master tran-
scription factors for Th2, GATA3 [32] and the Retinoid X
Receptor (RXR) [33], were induced under the PMA/CD28
stimulatory condition. Notably, Th2-associated cytokines
like IL-4, IL-5 and IL-13 were not induced in Jurkat T
cells after PMA/CD28-stimulation, this in contrast with
PMA/CD28 stimulation of human whole blood and puri-
fied CD4+ T cells, which could be due to the developmen-
tal blockage of Jurkat T cells. Additional file 6: Figure 2
shows a schematic overview summarizing the involvement
of the signaling pathways and genes induced under differ-
ential stimulation as observed in this study and highlights
their relation towards T helper 1 and -2 development.
Our results are in line with the notion that high calcium
levels drive Th1 and CTL responses and low calcium
levels drive Th2 responses [7,34,35], which was further
substantiated by our results using inhibitors for Lck and
Cn, which modulate Calcium signaling in T cells. These
inhibitors repressed Th1-associated genes under PMA/
CD3-stimulation, but induced Th2 transcription factors
GATA3 and RXRA, revealing a skewing of Th1 towards
Th2 profiles. In contrast, PMA/CD28 stimulation in the
presence of Lck and Cn inhibition, Th2-associated genes,
e.g. CCL1 or IL-13 in CD4+ T cells, were not affected or
even induced. The crucial role of Calcium and Lck in driv-
ing Th1 response is in line with the observation that knock
down of Lck affects the virus-specific Th1/CTL response
in mice and Lck deficiency increases Th2 associated cyto-
kine production [36,37]. Interestingly, lack of Calcium sig-
naling can give rise to an anergic T cell phenotype
(reviewed in [38]). Therefore it would be of interest to
further explore the role of Lck in calcium-dependent acti-
vation via PMA/CD3 on Th1/CTL responses and calcium-
independent activation of T cells via PMA/CD28 on the
induction of anergy in more detail.
CD28 signaling has been functionally linked with PKCθ
induced activation of NFB [39], which was also validated
using PMA/CD28 as stimulus [40]. Previously it has been
reported that CD28-costimulation induces GATA3
expression and Th2 differentiation via the activation of
NFB [41,42]. Additional studies in mice revealed that
PKCθ is involved in mounting both Th2- and Th1-
mediated lung inflammation, although Th2-mediated
inflammation is more PKCθ-dependent [43]. Our studies
show that inhibition of PKCθ can indeed inhibit a PMA/
CD28 stimulation, which was reflected by the effect of
PKCθ inhibition on the PMA/CD28-induced Th2-like
gene expression profile. These observations are in line
with the results from CD28 knock-out mice and inhibition
of CD28 signaling using CTLA4Ig, showing that the CD28
co-stimulatory signaling is crucial for mounting a proper
Th2 response. In contrast, Th1 and CTL responses were
found to be less dependent on CD28 signaling [44,45]. Of
interest, PKCθ inhibition in our hands, also affected PMA/
CD3-induced Th1-like expression profiles. These results
underline the duality of PKCθ in the integration of TCR
and CD28-mediated signaling events which is evident
from PKCθ KO mice experiments.
Finally, our results also show that this differential stimu-
lation does not only occur in Jurkat T cells, but also plays
a role in primary human T cells. These cells were found to
secrete a Th1-like response (Tbet-IFNg) via PMA/CD3 sti-
mulation, whereas PMA/CD28 stimulation led to a Th2
activation profile (GATA3-IL-5/IL-13). In these cells inhi-
bition of the Lck/Cn/NFAT pathway was only effective
after PMA/CD3 stimulation whereas inhibition of PKCθ
inhibited both PMA/CD3-induced IFNg production and
PMA/CD28-induced IL-13 production. These results illus-
trate that the findings in the Jurkat T cell line were suc-
cessfully translated and relevant to a human primary
cellular setting. Interestingly, PMA/CD3 stimulation also
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enhanced IL-17 production in the primary human whole
blood assay and increased the expression of the IL-21
receptor, which is crucial for Th17 induction [46,47], in
Jurkat T cells. These results suggest that additional signals,
like IL-21 in conjunction with TGFb and IL-6, might be
necessary to differentiate from a Th1-like phenotype
towards a Th17 phenotype, whereas the absence of TGFb
in the presence of high levels of IL-2 will favor Treg devel-
opment or stabilization. Therefore further exploration of
these differential stimulations in the presence of defined/
different cytokine stimuli could further elucidate T helper
cell differentiation and establish sub-set specific genome
profiles. The findings described in this paper offer a robust
platform for in vitro activation of T cells, in which
observed responses can be easily translated form Jurkat T
cells, towards purified CD4+ T cells and even human
whole blood. This can be of interest for efficiency and
selectivity profiling of kinase inhibitors or for pathway-spe-
cific biomarker identification for future drug development
and clinical studies.
Methods
Compounds
Inhibitors selectively targeting defined pathways used in
this study were A-420983 (1 μM; Lck inhibitor) [48], AEB-
071 (10 μM; PKCθ inhibitor) [49] and Cyclosporin A
(1 μM; Calcineurin inhibitor). Additionally, inhibitors of
the MAPK pathway, SP600125 (10 μM; pan JNK),
PD98059 (10 μM; MEK1/2), Org 48762-0 (10 μM; P38)
[50] were used. All compounds were dissolved in 100%
DMSO. Maximal and final concentration of DMSO used
in the culture assays was 0.1% v/v.
Cell culture
Jurkat E6.2.11 T cells were cultured in DMEM F12 med-
ium (#041-94895 M, Gibco) supplemented with 10% FBS
(#10099-141, Invitrogen) and 80 U/ml penicillin/80 μg/ml
streptomycin (#15140-122 Gibco). Cells were cultured at
concentrations between 1-2 × 105 cells/ml at 37°C/5%
CO2. Cells were stimulated for 15 minutes up to 24 hours
with anti-CD3 (1 μg/ml, OKT3), anti-CD28 (1 μg/ml, peri-
cluster CD28 #M1456 Sanquin, the Netherlands), PMA
(10 ng/ml, Sigma, USA) and ionomycin (1 μg/ml, Sigma,
USA), or combinations thereof.
For gene expression profiling Jurkat T cells were
seeded in T25 culture flasks at a concentration of 1 × 106
cells/ml (1 × 107 cells in total) and cultured overnight at
37°C/5%CO2, one day prior to stimulation. On the day of
the experiment cells were preincubated with the com-
pound of interest for 30 minutes, followed by a stimula-
tion with either CD3/CD28, PMA/CD28 or PMA/CD3,
at concentrations of 10 ng/ml PMA, 1 μg/ml CD3 and
1 μg/ml CD28. Jurkat T cells were cultured in the
presence or absence of stimulation for one or eight hours
in total, after which the cells were washed in ice cold
PBS. Thereafter cell pellets were collected and snap fro-
zen at -80°C. Cell pellets were stored until further
processing.
Isolation and quality check of mRNA
Total RNA was isolated from Jurkat T cells using the
RNeasy mini extraction kit (Qiagen # 74106) according
to the manufactures’ protocol. RNA was dissolved and
diluted in RNAse free water and the RNA concentration
was determined via Nanodrop analysis. The quality of
total RNA was evaluated by capillary electrophoresis
using an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Palo Alto, Calif.)
Double-stranded cDNA was synthesized from 1.5 μg
total RNA using the One-Cycle Target Labeling Kit (Affy-
metrix Santa Clara, CA), and used as a template for the
preparation of biotin-labeled cRNA using the GeneChip
IVT Labeling Kit (Affymetrix Santa Clara, CA). Biotin-
labeled cRNA was fragmented at 1 μg/μl following the
manufacturer’s protocol. After fragmentation, cRNA
(10 μg) was hybridized at 45°C for 16-17 hours to the
Human Genome U133A 2.0 Array or the Human Genome
U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA). Fol-
lowing hybridization, the arrays were washed, stained with
phycoerythrin-streptavidin conjugate (Molecular Probes,
Eugene, OR), and the signals were amplified by staining
the array with biotin-labeled anti-streptavidin antibody
(Vector Laboratories, Burlingame, CA) followed by phy-
coerythrin-streptavidin. The arrays were laser scanned
with an GeneChip Scanner 3000 6 G (Affymetrix, Santa
Clara, CA) according to the manufacturer’s instructions.
Data was saved as raw image file and quantified using
GCOS (Affymetrix).
Statistical analysis
The .CEL files were analyzed with the R http://www.r-
project.org and the BioConductor software package
http://www.bioconductor.org. Normalization was done
using gcrma. Building of the experimental design and cal-
culation of the ratios was done with the limma package.
Regulated probe sets were selected on basis of the fold
change and the adjusted p-value (Benjamini-Hochberg
correction). Multivariate data analysis and clustering was
done with standard methods in the R software package
http://www.r-project.org. For the principal component
analysis and hierarchical clustering, ratio data were used.
The ratio data were calculated for each treatment to its
corresponding control. For the treatment with the sti-
muli, the untreated cells were taken as a control. For the
treatment with stimulus + compound combinations, the
treatment with the stimulus alone was taken as a control.
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Results were expressed as mean ± SEM. Significance
of differences was determined using a one-way ANOVA
followed by post-hoc testing as indicated.
Data sets can be found in GEO http://www.ncbi.nlm.
nih.gov/gds/ under accession number GSE30678.
FLIPR calcium flux assay
96-wells plates were coated with poly-L-lysine in PBS
for 1 h at 37°C. Jurkat T cells were seeded at a concen-
tration of 7 × 105 in culture medium and rested for 1
hour at 37°C/5%CO2. Thereafter cells were incubated
for 1 hour in the dark with FLIPR calcium buffer,
according to the manufacturers’ protocol. Stimuli were
added via the Flexstation384 and calcium release was
monitored in time (Molecular devices, Sunnyvale,
USA).
Western blotting and nuclear translocation assay
Cells were washed in ice-cold PBS and pellets were lysed
on ice in lysis buffer (Biosource, cat nr FNN0011, supple-
mented with 1 × protease inhibitor cocktail Roche cat no
11873580051, 1 mM PMSF Fluka cat no 93482, phospha-
tase inhibitor cocktail I, Sigma cat no P2850, phosphatase
inhibitor cocktail II, Sigma cat no P5726) followed by an
incubation for 30 min on ice. The lysates were stored at
-80°C until further analysis.
Phosphorylation of proteins from stimulated Jurkat cells
were evaluated via western blot analysis. Briefly, samples
were run on a 4-12% NuPage gels (#NP321BOX, Invitro-
gen) for 35 min on 200 V in 1 × MES buffer (#NP0002,
Invitrogen, USA) and subsequently transferred to a PVDF
membrane (#162-0184, Biorad). The blots were blocked in
PBS/0.05% Tween-20 with 1% skim milk (#232100, Difco)
and 1% BSA. Blots were incubated O/N at 4°C in a roller
bottle with the primary antibody diluted 1:1000 in block
buffer, followed by incubation with a secondary detection
antibody. Thereafter blots were incubated in ECL
(#RPN2106V1 and RPN2106V2 Amersham Pharmacia)
and hyperfilms (#RPN3103K, Amersham Pharmacia) were
exposed and developed. For the detection the following
antibodies were used: pLck/Src (Tyr416 Cat N° 2101 L),
Lck (Cat N° 2752), pZAP70 (Tyr319 Cat N° 2701), pPKCθ
(Thr538, Cat N° 9377), pMARCKS (Ser152/156 Cat N° 4273)
and ATF-2 (Thr71 Cat N° 9221) (all cell signaling technol-
ogy, Danvers, USA). pP38 (Thr180/Tyr182 Cat N° 44-684
G), pERK (Thr185/Tyr187 Cat N° 44-680 G), pJNK1/2
(Thr183/Tyr185 Cat N° 44-682 G), JNK1 (Cat N° 44-690 G)
were obtained from Invitrogen (Carlsbad, USA) and c-Jun
(pSer73) was obtained from calbiochem (cat no 420114).
For the analysis of nuclear translocation of the transcrip-
tion factors NFAT, NFkBp65 and c-JUN, nuclear fractions
of activated Jurkat T cells were isolated via hypotonic
shock and levels of activated transcription factors in the
nuclear lysates was tested in a TransAM transcription
factor ELISA according to the manufacturers’ protocol
(Active Motif, Carlsbad, USA).
Knock down of PKCθ and lck in Jurkat T cells
Jurkat T cells (2 × 10e7 cells/ml) were mock transfected or
electroporated (250 V/975 μF) with siRNA targeting Lck
(RefSeq accession-number NM-005356; sense 5’-GCACG-
CUGCUCAUCCGAAAdTdT) and PKCθ (RefSeq acces-
sion-number NM-006257; sense 5’-GCAGCAAUUUCGA
CAAAGAdTdT) in different concentrations of 500, 100
and 20 nM or scrambled control siRNA (Thermo scienti-
fic, Dharmacon Inc, Lafayette, USA). Electroporated cells
were cultured in M505 supplemented with 10% FCS. Cells
were stimulated 72 hours after electroporation and knock-
down efficiency of the specified proteins was checked via
western blot analysis. Culture supernatants of PMA/CD28
or PMA/CD3-stimulated cells were collected after
24 hours and production of respectively CCL1 and IL-2
was determined.
Experiments with WBA
Peripheral whole blood was obtained by venipuncture
from healthy adults (male/female) and was collected into
lithium heparinised tubes. Blood was obtained from
healthy volunteers and the time between puncture and
processing was less than 1 hour. Blood was diluted 1:4
with RPMI 1640 (Life Technologies, cat no. 32404-014)
supplemented with penicillin/streptomycin (GibcoBRL, cat
15140-122) and 2 mM L-glutamine (GibcoBRL, cat 25030-
024) and distributed (200 μl/well) into 96-wells plates
(Nunc, Cat 167008). Blood cultures were stimulated with
soluble aCD3/PMA and soluble aCD28/PMA, or left
unstimulated. Blood (200 μl/well) in RPMI 1640 medium
was incubated with 25 μl compound (maximum of 0.1%
v/v DMSO).
Cytokine determination
Cytokines and chemokines IL-2, CCL1/I309 and XCL1,
secreted into the supernatant of stimulated Jurkat T cells
were determined via ELISA (R&D systems, USA). Cyto-
kines IL-17, IFNg, IL-13 and IL-5, produced by human
CD4+ T-cells activated in whole blood, cultured in the
presence or absence of compounds were determined in
the culture supernatant, using a bead-based human cyto-
kine multiplex kit (Bioplex-system; Bio-Rad, Veenendaal,
The Netherlands) according to the manufacturer’s instruc-
tions. Culture suppernatants were collected at day 1 of
culture. Samples were analyzed using a Luminex-100 ana-
lyzer (Luminex, Austin, USA) with Bio-plex Manager Soft-
ware 3.0 (Bio-Rad). Proteins were discriminated based on
the fluorescent label of the bead and the PE levels were
corrected for background levels of negative controls. The
sensitivity of the cytokine assay was less than 5 pg/ml for
all cytokines measured.
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cDNA synthesis and q-PCR
Primary human CD4+ T cells were isolated from buffy
coats from three healthy donors using MACS negative
CD4+ purification technology (Miltenyi biotech,
Germany), yielding a overall 96% pure CD4+ T cell popu-
lation. RNA from stimulated CD4+ T cells was isolated
using an RNeasy minikit (QIAGEN Gmbh, Germany).
RNA content of samples was analyzed using Nanodrop
(Agilent technologies, Ca, USA) and purity was analyzed
using the Agilent RNA 6000 nanokit protocol on the
RNA nano labchip using the Agilent 2100 bioanalyzer
(Agilent technologies, Waldborn, Germany). Three
microgram of RNA was used for cDNA synthesis using
random hexamer primer mix (invitrogen), 10 mM dNTP,
M-MLV RT buffer and M-MLV Reverse transcriptase
(Promega). RT reaction was performed at 42°C for
1 hour followed by a deactivation for 5 minutes at 90°C.
cDNA of the Th1 master transcription factor Tbx21
(Tbet), Th2 transcription factor GATA3 or the control
household gene RPL19 was applified using Power SYBR
green mastermix (Applied Biosystems, Warrington, UK)
and expression was monitored on the ABI prism 7900
HT sequence detection system (Applied Biosystems,
Warrington, UK), Ct values were normalized for the
expression of the RPL19 gene.
Additional material
Additional file 1: Figure S1. PCA using the ratio data vs. the
respective controls. Cells were treated for 8 hours with the single
stimuli CD28, CD3 and PMA (black squares) and with the stimulatory
combinations PMA/CD28 (blue circles) CD3/CD28 (green triangles) and
CD3_PMA (red diamonds). The corresponding treatments with the
stimulus + inhibitor combination are represented by the same symbols.
Eg. the red diamond with the AEB071 label represents the samplein
treated with CD3 + PMA and AEB071. This graph shows that PMA/CD28
stimulation was mainly affected by AEB071, whereas PMA/CD3
stimulation was mainly modulated by CsA, A420983 and AEB071. The
symbols around the origin represent the treatments with the MAPK
inhibitors, which only had a marginal effect on the stimuli used (the
labels have been omitted for clarity). The numbers denote the number
of significantly regulated probe sets for these conditions compared to
the respective controls. These numbers were very low for the conditions
including MAPK inhibitors and CD28 stimulation alone and for A420983
and CsA after PMA/CD28 stimulation (centered around the origin of the
graph) and have therefore been omitted for clarity. For details of
regulated probe sets for all conditions and the overlap between these
sets, see Additional file 2: Table S1. Repeating this analysis with different
values for the fold change and p-value cut off yielded essentially the
same results for the multivariate analysis.
Additional file 2: Table S1. For each treatment, regulated probe sets
were selected by comparison with the corresponding control. Probe sets
were identified as being significantly regulated if adjusted p-value was <
10-10 and fold change > 4. The numbers in each cell show the number
of overlapping genes between two treatments. The cells highlighted in
grey indicate the most informative numbers because in these
comparisons, only one of the parameters is changed between two
conditions. The other numbers are shown for the sake of completeness,
but are less informative because the comparisons are between
treatments in which two parameters at the same time have been
changed.
Additional file 3: Files S1. Each of these files contain 4 columns. The
first is the Affymetrix probe set id, the second columns gives the
Euclidean distance to the gene expression profile of interest (file 1: CCL1,
file 2: IL-2, file 3: EGR1). The third and fourth columns show the
corresponding gene symbol and description respectively.
Additional file 4: Files S2. Each of these files contain 4 columns. The
first is the Affymetrix probe set id, the second columns gives the
Euclidean distance to the gene expression profile of interest (file 1: CCL1,
file 2: IL-2, file 3: EGR1). The third and fourth columns show the
corresponding gene symbol and description respectively.
Additional file 5: Files S3. Each of these files contain 4 columns. The
first is the Affymetrix probe set id, the second columns gives the
Euclidean distance to the gene expression profile of interest (file 1: CCL1,
file 2: IL-2, file 3: EGR1). The third and fourth columns show the
corresponding gene symbol and description respectively.
Additional file 6: Figure S2. A schematic presentation of signaling
pathways and induced gene profiles via differential stimulation of T cells.
This figure highlights the findings of this study indicating that TCR/CD3-
induced Calcium signaling is necessary for efficient T helper 1
development, whereas absence of calcium signaling and sufficient
activation of NFB/AP1 lead to T helper 2 development (as indicated by
green-red intensity plots). A selected list of genes is listed derived from
the IL-2 and CCL1 gene profiles shown in Figure 7.
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